Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520117 | 0.77 | NUDT1 (0.46) | NUDT1L3MBTL1 | |
| SCHEMBL9935446 | 0.77 | NUDT1 (0.52) | NUDT1L3MBTL1 | |
| SCHEMBL5405262 | 0.75 | HTR2C (0.47) | NUDT1KEAP1L3MBTL1ADORA2A | |
| SCHEMBL3523865 | 0.72 | NUDT1 (0.42) | NUDT1L3MBTL1 | |
| SCHEMBL5411848 | 0.69 | TLR7 (0.33) | — | |
| SCHEMBL16061457 | 0.69 | NUDT1 (0.42) | NUDT1KEAP1L3MBTL1ADORA2A | |
| SCHEMBL8332978 | 0.68 | LOXL2 (0.36) | LOXL2 | |
| SCHEMBL335977 | 0.64 | NUDT1 (0.58) | NUDT1KEAP1L3MBTL1ADORA2A | |
| SCHEMBL20265413 | 0.64 | NUDT1 (0.52) | NUDT1L3MBTL1ADORA2A | |
| SCHEMBL12559813 | 0.64 | NUDT1 (0.52) | NUDT1L3MBTL1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | NUDT1 3312/4885KEAP1 577/4885L3MBTL1 4405/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | NUDT1 1688/4885KEAP1 1293/4885L3MBTL1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.